Lajos Pusztai MD, D.Phil.

Professor of Medicine (Medical Oncology); Chief of Breast Medical Oncology; Co-Director, Cancer Genetics Research Program

Specialties & Subspecialties

Cancer Center, Yale: Breast Cancer Program

Medical Oncology

Education & Training

  • M.D., Semmelweis University School of Medicine, Budapest, Hungary (1987)
  • D.Phil., University of Oxford (1993)
  • Fellow, University of Texas Anderson Cancer Center , Medical Oncology (1996 - 1999)
  • Residency, University of Rochester St. Mary's Hospital , Internal Medicine (1994 - 1996)
  • Intern, University of Rochester St. Mary's Hospital , Internal Medicine (1993 - 1994)

Patient Care

Accepts New Patients? Yes | Patient Type: Adult | Accepts referrals from patients


Clinical Interests

breast cancer; cancer genetics.


Cancers Treated

Breast


Board Certifications

  • Medical Oncology, Board Certified (1999)

Clinical Trials

ConditionsStudy Title
Breast - FemaleA Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less (SWOG S1007) (CIRB)
Breast - FemaleSINGLE ARM, NEOADJUVANT, PHASE II TRIAL OF PERTUZUMAB AND TRASTUZUMAB ADMINISTERED CONCOMITANTLY WITH WEEKLY PACLITAXEL AND FEC FOR CLINICAL STAGE I-III HER2-POSITIVE BREAST CANCER
Anus, Bladder, Breast - Female, Breast - Male, Cervix Uteri, Colon, Esophagus, Kidney, Larynx, Liver, Lung, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, and Other Respiratory and Intrathoracic OrgansAN OPEN-LABEL, PHASE I, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC-0032 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS AND IN COMBINATION WITH ENDOCRINE THERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HORMONE RECEPTOR-POSITIVE BREAST CANCER
Breast Cancer, Cancer, and Breast - FemaleExamination of Epigenetic Changes in Breast Tissue and Peripheral Blood of Women at Average versus Increased Risk of Breast Cancer
Breast - FemaleA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer

More Clinical Trials...

Edit Profile